Cipher Gene
Latest round
- Series C
Last raised
- May 2024
Total raised
- $31M
Investors
- 12
About Cipher Gene
Established in 2015 and based in Beijing, China, Cipher Gene LLC is a biotech company that focuses on the analysis of big data in the field of children's genetic diseases. The company has production and operation centers, as well as a high-throughput drug screening R&D center in the Yangtze River Delta region. With a team of researchers from institutions such as Harvard University and the National Institutes of Health, Cipher Gene has a background in clinical molecular genetics. The CEO, Dr.D. in Biomedicine from East China Normal University and has served as a scientist at the National Cancer Institute of the NIH. The company has established stable cooperative relationships with over 300 medical and research institutions, including Peking University First Hospital and Xiangya Hospital of Central South University. Meanwhile, the company has completed nearly 70 international academic papers and obtained more than 150 patents and intellectual property rights, and has received honors including being named as a "High-tech Enterprise". The company focuses on the research and development of clinical diagnostic and prevention products for genetic diseases, offering a series of solution from newborn screening to genetic disease diagnosis and functional validation. Specific products include NGS-type whole exome testing for genetic diseases, whole genome sequencing, and so on. Its iWES product significantly enhances the positive detection rate with zero false positives, and its high-throughput drug screening platform facilitates the development of precision treatment drugs. Cipher Gene also provides translational medicine services that bridge clinical practice with scientific research. The company generates revenue by providing genetic testing solutions and precision medical services, as well as offering high-throughput drug screening and translational medicine services to clients in the healthcare and pharmaceutical industries.
Who invested in Cipher Gene
12 investors across 4 rounds
See all investors in Cipher Gene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cipher Gene
Who invested in Cipher Gene?
Cipher Gene has 12 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cipher Gene raised?
Cipher Gene has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Cipher Gene last raise money?
Cipher Gene's most recent round on record is a Series C, in May 2024.
What does Cipher Gene do?
Established in 2015 and based in Beijing, China, Cipher Gene LLC is a biotech company that focuses on the analysis of big data in the field of children's genetic diseases.
Where is Cipher Gene headquartered?
Cipher Gene is headquartered in Beijing, China.
Which VCs invest in companies like Cipher Gene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Cipher Gene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Cipher Gene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.